Oral drug that targets two cancer drivers tested in first human study
Disease control
By invitation only
Researchers are testing an experimental oral drug called ND-003 in Chinese patients with advanced solid tumors that have worsened after standard treatment or have no standard options left. ND-003 blocks two proteins, NTRK and RET, that can drive cancer growth when altered. The ph…
Phase 1 • Sponsor: Shenzhen NewDEL Biotech, Co., Ltd • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC